Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer
一项随机、双盲、安慰剂对照、多中心II期研究,旨在评估阿普昔布联合多西他赛或培美曲塞治疗生物标志物筛选的非小细胞肺癌患者的疗效和安全性。
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2014.55.5789
Edelman, Martin J; Tan, Ming T; Fidler, Mary J; Sanborn, Rachel E; Otterson, Greg; Sequist, Lecia V; Evans, Tracey L; Schneider, Bryan J; Keresztes, Roger; Rogers, John S; de Mayolo, Jorge Antunez; Feliciano, Josephine; Yang, Yang; Medeiros, Michelle; Zaknoen, Sara L